Renovaro Biosciences Statistics
Share Statistics
Renovaro Biosciences has 162.39M
shares outstanding. The number of shares has increased by 5.5%
in one year.
| Shares Outstanding | 162.39M |
| Shares Change (YoY) | 5.5% |
| Shares Change (QoQ) | 2.32% |
| Owned by Institutions (%) | 14.13% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,364 |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 5.1M, so 3.21% of the outstanding
shares have been sold short.
| Short Interest | 5.1M |
| Short % of Shares Out | 3.21% |
| Short % of Float | 4.62% |
| Short Ratio (days to cover) | 7.74 |
Valuation Ratios
The PE ratio is -1.86 and the forward
PE ratio is null.
Renovaro Biosciences's PEG ratio is
-0.1.
| PE Ratio | -1.86 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.14 |
| P/FCF Ratio | -13.6 |
| PEG Ratio | -0.1 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Renovaro Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.34 |
| Interest Coverage | -80.73 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,226,006.88 |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.01% in the
last 52 weeks. The beta is 0.61, so Renovaro Biosciences's
price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | -67.01% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.7 |
| Relative Strength Index (RSI) | 39.34 |
| Average Volume (20 Days) | 1,466,972 |
Income Statement
| Revenue | n/a |
| Gross Profit | -121.86K |
| Operating Income | -81.64M |
| Net Income | -80.65M |
| EBITDA | -81.52M |
| EBIT | -79.64M |
| Earnings Per Share (EPS) | -0.84 |
Full Income StatementBalance Sheet
The company has 220.47K in cash and 3.79M in
debt, giving a net cash position of -3.57M.
| Cash & Cash Equivalents | 220.47K |
| Total Debt | 3.79M |
| Net Cash | -3.57M |
| Retained Earnings | -332.46M |
| Total Assets | 117.73M |
| Working Capital | -25.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.97M
and capital expenditures -70.43K, giving a free cash flow of -11.04M.
| Operating Cash Flow | -10.97M |
| Capital Expenditures | -70.43K |
| Free Cash Flow | -11.04M |
| FCF Per Share | -0.11 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
